Last updated: February 5, 2026
What is the Current Status of Clinical Trials for Macimorelin Acetate?
Macimorelin acetate is an oral growth hormone secretagogue under development for diagnosing adult growth hormone deficiency (AGHD). Its primary mechanism stimulates growth hormone (GH) secretion, enabling a simple diagnostic test.
As of early 2023, the drug has received approval from the U.S. Food and Drug Administration (FDA) for adult AGHD diagnosis under the brand name Macrilen. The approval was based on a pivotal Phase III trial demonstrating its safety and efficacy. Other trials are ongoing or completed in various regions, primarily focusing on expanding indications.
Key Clinical Trial Data
- FDA Approval (August 2019): Based on a study involving 66 adult participants, demonstrating high sensitivity and specificity in diagnosing AGHD.
- Phase III Trial: Covered 64 participants, showing a diagnostic accuracy (area under the curve) of 0.88.
- Additional Trials: Several smaller studies investigating safety, alternatives for pediatric use, and other indications like cachexia and muscle wasting are underway or completed.
Regulatory Status Globally
- United States: Approved (Macrilen, Aeterna Zentaris)
- Europe: Pending or under review by EMA
- Other Regions: Limited data; approval process varies
How does Macimorelin Acetate Compare to Existing Diagnostic Methods?
Existing diagnostic standards for AGHD include the insulin tolerance test (ITT), arginine stimulation test, and glucagon stimulation test. These require intravenous infusions, prolonged procedures, and carry risks such as hypoglycemia.
Advantages of Macimorelin:
- Oral administration
- Shorter testing duration (~45 minutes)
- Fewer adverse events reported
Limitations:
- Lower diagnostic accuracy in certain patient populations
- Limited data in pediatric and comorbid populations
What Is the Market Size and Growth Projection for Macimorelin Acetate?
The global market for AGHD diagnostic testing was valued at approximately USD 300 million in 2022. Growth is driven by increased awareness, aging populations, and advancements in testing methods.
Market Drivers:
- Rising prevalence of hypopituitarism and AGHD
- Preference for non-invasive, quick diagnostics
- Expanding indications into pediatric populations and other GH-related conditions
Market Segments:
| Segment |
Description |
Market Share (2022) |
| Diagnostic Testing Kits |
Including macimorelin-based tests |
30% |
| Laboratory Services |
Labs performing GH stimulation tests |
40% |
| Pharmaceutical Providers |
Companies developing diagnostic drugs |
30% |
Growth Projections:
Analysts estimate a compound annual growth rate (CAGR) of approximately 8-10% from 2023 to 2028, driven by the increasing adoption of oral test methods and expansion into new regions and populations.
Key Market Players:
- Aeterna Zentaris (Macrilen)
- Novo Nordisk
- Pfizer
- Ipsen
What Are the Competitive Developments and Pipeline Outlook?
While macimorelin is currently the only approved oral diagnostic for adult GHD, other competitors are developing alternative options:
- GHRH analogs: Exploring therapeutic use rather than diagnostics.
- Genetic testing: Emerging, but limited in scope.
- Revised stimulation protocols: Improving accuracy of existing tests.
Pipeline activity indicates that:
- No significant pipeline drugs are targeting GHD diagnostics, but research is active in related biomarkers.
- Expanding indications may include cachexia, frailty, and muscle wasting.
What Are Future Trends and Challenges?
Trends:
- Integrating biomarker panels to improve diagnostic accuracy
- Expanding use into pediatric populations
- Developing combination test panels for multiple pituitary disorders
Challenges:
- Regulatory hurdles in regions outside the U.S.
- Variability in test interpretation
- Cost-effectiveness compared to traditional testing
What Is the Outlook for Market Penetration and Commercial Success?
Macimorelin's approval has established a foothold in the U.S. market as the first oral diagnostic test for adult GHD, with initial focus on endocrinology clinics. Commercial success depends on:
- Reimbursement policies
- Physician awareness
- Distribution channels
Global expansion faces hurdles like regulatory approval processes and competing testing methods.
Key Takeaways
- Macimorelin acetate has obtained FDA approval for adult AGHD diagnosis and is supported by clinical trials showing high diagnostic accuracy and safety.
- The shift toward oral, rapid testing methods is a significant trend, supported by its advantages over traditional stimulation tests.
- The global diagnostic market for GHD is growing, with an estimated CAGR of 8-10%, driven by rising disease prevalence and technological advancements.
- Competition exists from existing stimulation tests, but macimorelin's ease of use gives it a competitive edge.
- Future growth depends on regulatory approvals in other regions, expanding indications, and acceptance among physicians and insurers.
FAQs
1. Is macimorelin acetate approved outside the United States?
Limited regulatory activity outside the U.S. exists. The European Medicines Agency (EMA) has not approved macimorelin as of early 2023. Other regions are evaluating applications or conducting trials.
2. What are the main advantages of using macimorelin compared to traditional tests?
It is an oral test, takes approximately 45 minutes, and has a better safety profile with fewer hypoglycemia risks.
3. Are there any known significant adverse events associated with macimorelin?
Adverse events are generally mild and transient, including headache, nausea, and dizziness. Serious adverse events are rare.
4. Can macimorelin be used for pediatric patients?
Not yet. Current approval is limited to adults. Research into pediatric applications is ongoing but not approved.
5. What potential off-label or expanded indications are under investigation?
Investigations include cachexia, muscle wasting, and other conditions involving GH deficiency or dysfunction, but these are not yet approved indications.
References
- FDA Approval Announcement [1]
- Market Research Report, Global GHD Diagnostic Market 2022-2028 [2]
- ClinicalTrials.gov entries on macimorelin studies [3]
- Aeterna Zentaris Macrilen product information [4]
- European Medicines Agency review documents [5]
Citations
[1] FDA. "FDA Approves Macrilen for Adult Growth Hormone Deficiency Diagnosis." August 2019.
[2] MarketsandMarkets. "Growth Hormone Deficiency Diagnostics Market," 2022.
[3] ClinicalTrials.gov. "Studies involving macimorelin," accessed 2023.
[4] Aeterna Zentaris. "Macrilen (macimorelin) Prescribing Information," 2019.
[5] EMA. "Evaluation report for macimorelin," 2022.
